Great mental health care for all

We build solutions to make effective mental health care accessible to everyone, on their terms.

For those who are able to get care, 82% are given medication – but medication isn’t always the best option.2


of people taking SSRIs experience moderately severe side effects.3


remission rate for the most common medications.4,5


of people prefer a non-drug option.6

Our digital treatments deliver effective care with no serious side effects

Daylight7 and Sleepio8 are easily accessible, safe, and highly effective.

Our digital programs provide tailored support for adolescents living with depression

Spark Direct shows notable effectiveness in enhancing emotional well-being in practical, real-world scenarios.9

Trusted by the world’s leading organizations

For nearly a decade, we’ve been empowering employers and health plans to help millions back to good mental health.

Simple to adopt,
low-lift engagement

The medication assessment program from Big Health is the easiest way to offer non-drug options to members of your population in need.

Add coverage to your
pharmacy plan

Pre-approved by major pharmacy benefit managers, add coverage in as few as 10 days.

Offer access via
existing care pathways

Easily reach members when they need it.

Bill via pharmacy invoice

Deep integrations mean you get to bill via your pharmacy invoice.

We believe evidence
is a duty, not a chore

We’re committed to gold-standard clinical evidence. We have over 90 peer-reviewed publications with more than 28,000 participants, including 18 randomized controlled trials (RCTs).


of participants experienced clinical improvement in insomnia.7


of participants experienced clinical improvement in anxiety.8

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.

Spark Direct is a digital program that may help individuals live well with major depressive disorder (MDD) and symptoms of depression by providing them with cognitive and behavioral techniques that can improve mood. Spark Direct has not been reviewed or approved by the Food & Drug Administration and is not intended to diagnose or treat any medical condition. Please read the instructions for use.

1. The State of Mental Health in America. Mental Health America. (n.d.). Retrieved from:
2. Terlizzi, E. P., & Zablotsky, B. (2020). Mental Health Treatment Among Adults: United States, 2019. NCHS Data Brief, (380), 1-8.
3. Demyttenaere, K., Albert, A., Mesters, P., Dewè, W., De Bruyckere, K., & Sangeleer, M. (2005). What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? Journal of Clinical Psychiatry, 66(7), 859-863.
4. Mojtabai R, Amin-Esmaeili M, Spivak S, et al. Remission and treatment augmentation of depression in the United States. J Clin Psychiatry. 2021;82(6):21m13988.
5. Rickels, K., & Rynn, M. (2002). Pharmacotherapy of generalized anxiety disorder. Journal of Clinical Psychiatry, 63, 9-16
6. McHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A., & Otto, M. W. (2013). Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. The Journal of clinical psychiatry, 74(6), 0-0.
7. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.
8. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and anxiety, 37(12), 1168-1178.
9. Internal Data, November 2023

DOC-737 Effective 11/2023